HLT:PA:PA-Lyxor Index Fund - Lyxor STOXX Europe 600 Healthcare UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 155.885

Change

+1.36 (+0.88)%

Market Cap

USD 0.77B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.40 (+0.86%)

USD 55.36B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-10.50 (-1.83%)

USD 14.29B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-7.62 (-1.85%)

USD 13.82B
WRD:PA HSBC MSCI World UCITS ETF

-0.56 (-1.52%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-0.12 (-0.05%)

USD 9.11B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-14.30 (-2.84%)

USD 8.85B
WLD:PA Lyxor UCITS MSCI World D-EUR

-5.44 (-1.50%)

USD 7.99B
HHH:PA HSBC S&P 500 UCITS ETF

-1.05 (-1.81%)

USD 7.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

N/A

USD 6.91B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.13 (+1.68%)

USD 5.25B

ETFs Containing HLT:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.09% 84% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.09% 84% B 75% C
Trailing 12 Months  
Capital Gain 8.47% 42% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.47% 41% F 57% F
Trailing 5 Years  
Capital Gain 45.13% 49% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.13% 45% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.08% 54% F 61% D-
Dividend Return 9.08% 75% C 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.07% 86% B+ 92% A
Risk Adjusted Return 112.52% 94% A 97% N/A
Market Capitalization 0.77B 74% C 76% C+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike